Compare BSAC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | MRNA |
|---|---|---|
| Founded | 1977 | 2010 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 9.3B |
| IPO Year | 1994 | 2018 |
| Metric | BSAC | MRNA |
|---|---|---|
| Price | $29.72 | $27.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 13 |
| Target Price | $26.67 | ★ $33.91 |
| AVG Volume (30 Days) | 333.3K | ★ 9.9M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ 42.15 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $2,434,135,287.00 | $2,232,000,000.00 |
| Revenue This Year | $41.31 | N/A |
| Revenue Next Year | $5.39 | $0.77 |
| P/E Ratio | $12.84 | ★ N/A |
| Revenue Growth | ★ 20.98 | N/A |
| 52 Week Low | $18.19 | $22.28 |
| 52 Week High | $31.16 | $48.92 |
| Indicator | BSAC | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 60.85 |
| Support Level | $29.05 | $23.92 |
| Resistance Level | $29.58 | $26.00 |
| Average True Range (ATR) | 0.54 | 1.29 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 41.32 | 99.82 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.